logo
Plus   Neg
Share
Email

Wells Fargo Names Mike Santomassimo To Succeed John Shrewsberry As CFO - Quick Facts

Financial services company Wells Fargo & Co. (WFC) announced Tuesday that Mike Santomassimo will join the company in fall 2020 as Chief Financial Officer. Santomassimo will report to CEO Charlie Scharf and serve on the company's Operating Committee.

Santomassimo will succeed John Shrewsberry, who has announced plans to retire following a successful 22-year career with Wells Fargo, including the last six years as the company's CFO. Shrewsberry will continue in his role as CFO until Santomassimo joins the company and will assist with the transition thereafter.

Santomassimo, with more than 20 years of leadership experience in banking and finance, joins Wells Fargo from BNY Mellon, where he was CFO since 2018. Prior to joining BNY Mellon, he spent 11 years at JPMorgan Chase in a number of key finance leadership roles, including CFO for Banking.

He also served as CFO of JPMorgan's Securities Services & U.S. Private Banking businesses. He began his career at Smith Barney.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Despite the coronavirus pandemic, retailers are prepared for an early start to the holiday shopping season by offering discounts earlier so that consumers can buy and receive the gifts they want in time, the National Retail Federation or NRF said. The NRF also said it is launching a nationwide consumer education campaign called "New Holiday Traditions". Facebook (FB) has revealed new messaging features for Instagram, which will make it easier for users to stay in touch with others across Facebook's family of apps. The main change is that people using the Messenger app can now reach Instagram users, and vice versa. The users can control where they receive... Regeneron Pharmaceuticals, Inc. announced positive first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 in COVID-19 patients. REGN-COV2 rapidly reduced viral load and associated symptoms in infected COVID-19 patients. The company said it plans rapidly to discuss results with regulatory authorities.
Follow RTT